Tyrosine kinase inhibitors as next generation oncological therapeutics: Current strategies, limitations and future perspectives
Author:
Funder
Birla Institute of Technology and Science
Publisher
Elsevier BV
Subject
Pharmacology (medical)
Reference195 articles.
1. Adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?;Nurgali;Front Pharmacol,2018
2. The protein kinase complement of the human genome;Manning;Science,2002
3. PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials;Carles;Molecules,2018
4. Tyrosine kinase inhibitors: multi-targeted or single-targeted?;Broekman;World J Clin Oncol,2011
5. Regulation and targets of receptor tyrosine kinases;Pawson;Eur J Cancer,2002
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?;The AAPS Journal;2024-06-11
2. QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC Treatment;AAPS PharmSciTech;2024-05-06
3. Effect of macrocytosis on erlotinib response in metastatic non-small cell lung cancer;Journal of Surgery and Medicine;2023-08-31
4. Molecular basis and clinical application of targeted therapy in oncology;Medical Journal Armed Forces India;2023-03
5. Identification of the Major Degradation Pathways of Selumetinib;Pharmaceutics;2022-11-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3